Quantcast
Last updated on April 18, 2014 at 14:46 EDT

Latest Emmaus Medical Inc. Stories

2014-01-07 08:30:43

TORRANCE, Calif., Jan. 7, 2014 /PRNewswire/ -- Emmaus Medical, Inc. (the "Company," or "Emmaus"), a biopharmaceutical company engaged in the discovery, development and commercialization of innovative and cost-effective treatments and therapies primarily for rare and orphan diseases, today announced it has completed all patient visits for its Phase 3 clinical trial for the treatment of sickle cell disease. Emmaus expects top-line data from the Phase 3 clinical trial to be available in...

2013-05-09 08:30:36

Emmaus in Process of Completing Phase 3 Study For First Widely Available Treatment for Sickle Cell Disease TORRANCE, Calif., May 9, 2013 /PRNewswire/ -- Timothy Cote, M.D., MPH, former director of the Office of Orphan Product Development of the U.S. Food and Drug Administration, has joined Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, in an advisory capacity, the company announced today. Dr. Cote will advise Emmaus on the regulatory pathway for...

2012-12-19 16:23:51

TORRANCE, Calif., Dec. 19, 2012 /PRNewswire/ -- Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced that Peter Ludlum, the company's executive vice president and CFO, will give an overview of the company's Phase 3 sickle cell disease trial and discuss recent developments with its regenerative medicine research at the 6th Annual OneMedForum on January 8, 2013 at 9:50 a.m. P.T. at the Sir Francis Drake Hotel in San Francisco....

2012-12-03 08:27:35

TORRANCE, Calif., Dec. 3, 2012 /PRNewswire/ -- Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced the completion of patient enrollment for its phase 3 clinical trial to study L-glutamine as a treatment for sickle cell disease. "The completion of enrollment is a significant milestone for our company and the sickle cell community, moving one step closer to potentially bringing the first widely available treatment to patients...

2012-11-19 12:27:10

TORRANCE, Calif., Nov. 19, 2012 /PRNewswire/ -- Following a meeting on November 5, 2012 with the U.S. Food & Drug Administration (FDA), Dr. Yutaka Niihara offered the following remarks: "The FDA's review group unanimously recommended that we proceed to complete our Phase III trial without any modification to the protocol. The trial is directed to study L-glutamine as a treatment for sickle cell disease. "We currently have 220 patients enrolled at 32 study sites throughout the...

2012-07-17 06:26:34

TORRANCE, Calif., July 17, 2012 /PRNewswire/ -- Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company's investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease. The EC designation follows the recommendation of the European Medicines Agency's (EMA) Committee for...

2012-05-29 02:25:58

TORRANCE, Calif., May 29, 2012 /PRNewswire/ -- Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of...

2010-05-18 07:00:00

LOS ANGELES, May 18 /PRNewswire/ -- Emmaus Medical, Inc., the privately-held pharmaceutical company developing and bringing to market a promising new treatment for sickle cell disease, announced today that Henry (Hank) McKinnell Jr., PhD, has joined the board of directors. Dr. McKinnell is the former chief executive officer and former chairman of the board of directors of Pfizer Inc. The announcement comes as the company pursues final FDA approval of its sickle cell disease treatment....

2008-07-05 21:00:05

By Melissa Evans After years of clinical trials and research, Dr. Yutaka Niihara came up with a treatment for sickle cell anemia that was so simple he almost didn't believe it. L-Glutamine, one of the most common amino acids produced in the body and found abundantly in protein-rich foods, bloated the sickle- shaped cells that cause immense pain for thousands of people who suffer from the disease. "It's such a simple and safe treatment," said Niihara, who made the discovery while...